Physician profile
Paul Frederick
NPI 1366735623
$6,100.50
in general payments reported to CMS, 2019-2025
27 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $448 · 2021: $1,426 · 2022: $888 · 2023: $604 · 2024: $1,121 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,508.95 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $616.65 | 2019-2025 | Cequa |
| Allergan, INC. | $596.39 | 2019-2022 | |
| Abbvie INC. | $425.25 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $409.25 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $326.00 | 2021-2025 | Catalys System, Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $303.58 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $233.47 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $208.51 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $200.50 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $185.16 | 2021 | |
| Oyster Point Pharma, INC. | $179.99 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $178.39 | 2019-2023 | Flarex |
| Baxter Healthcare | $162.86 | 2022 | |
| Horizon Therapeutics Plc | $93.53 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $86.03 | 2019 | |
| Rxsight INC | $61.48 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Mallinckrodt Hospital Products INC. | $56.47 | 2022-2025 | Acthar |
| Harrow Eye, LLC | $55.60 | 2025 | Vevye |
| Dompe US, INC. | $43.04 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $36.07 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.81 | 2022 | |
| Glaukos Corporation | $31.30 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $26.41 | 2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Hologic Sales and Service, LLC | $13.91 | 2024 | Myosure Tissue Removal Device, Coolseal Generator |
| Carl Zeiss Meditec USA, INC. | $13.03 | 2022 | |
| Travere Therapeutics, INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.